1. Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxelAndrej Žist, Eitan Amir, Alberto Ocaña, Boštjan Šeruga, 2015, izvirni znanstveni članek Povzetek: Men with metastatic castrate-resistant prostate cancer (mCRPC) may not receive docetaxel in everyday clinical practice due to comorbidities. Here we explore the impact of comorbidity on outcome in men with mCRPC treated with docetaxel in a population-based outcome study. Methods. Men with mCRPC treated with docetaxel at the Institute of Oncology Ljubljana between 2005 and 2012 were eligible. Comorbidity was assessed by the age-adjusted Charlson comorbidity index (aa-CCI) and adult comorbidity evaluation (ACE-27) index. Hospital admissions due to the toxicity and deaths during treatment with docetaxel were used as a measure of tolerability. Association between comorbidity and overall survival (OS) was tested using the Cox proportional hazards analysis. Results. Two hundred and eight men were treated with docetaxel. No, mild, moderate and severe comorbidity was present in 2%, 32%, 53% and 13% using aa-CCI and in 27%, 35%, 29% and 8% when assessed by ACE-27. A substantial dose reduction of docetaxel occurred more often in men with moderate or severe comorbidity as compared to those with no or mild comorbidity. At all comorbidity levels about one-third of men required hospitalization or died during treatment with docetaxel. In univariate analysis a higher level of comorbidity was not associated with worse OS (aa-CCI HR 0.99; [95% CI 0.87%1.13], p = 0.93; ACE-27: HR 0.96; [95% CI 0.79%1.17], p = 0.69).
Ključne besede: metastatic castration-resistant prostate cancer, prostate cancer, comorbidity, chemotherapy
Objavljeno v DiRROS: 22.04.2024; Ogledov: 56; Prenosov: 21
 Celotno besedilo (428,78 KB) |
2. Influence of housing conditions on reliability of immunocastration and consequences for growth performance of male pigsKevin Kress, Ulrike Weiler, Sonja Schmucker, Marjeta Čandek-Potokar, Milka Vrecl, Gregor Fazarinc, Martin Škrlep, Nina Batorek Lukač, Volker Stefanski, 2020, izvirni znanstveni članek Povzetek: Immunocastration is a sustainable alternative to piglet castration but faces limited market acceptance. The phenomenon of non-responders has not to date been examined in detail, but adverse and stressful housing conditions (e.g., mixing of groups) might impair the success of vaccinations. Therefore, we evaluated the influence of housing conditions on the immune response after two Improvac® vaccinations at an age of 12 and 22 weeks, respectively. Boars, immunocastrates and barrows (n = 48 each) were assigned to three different housing conditions (n = 36 enriched, n = 36 standard n = 72 repeated social mixing). Immune response was quantified by measuring GnRH-binding and its consequences for testosterone concentrations, development of the genital tract and boar taint. Growth performance was evaluated via average daily gain (ADG). GnRH-binding and testosterone levels revealed that immunocastration reliably suppressed testicular functions after the 2nd vaccination. Housing conditions did not modify testicular function but influenced ADG as animals under mixing grew slower than those under enriched conditions. Gonadal status had only a slight impact on ADG except in immunocastrates, which showed a temporarily higher ADG after the 2nd vaccination. The results show that immunocastration is a reliable procedure under different housing conditions and competitive in terms of growth performance.
Ključne besede: immunocastration, vaccination, Improvac, non-responder, immune response, housing conditions, surgical castration, boar taint, growth performance, genital tract
Objavljeno v DiRROS: 06.09.2022; Ogledov: 633; Prenosov: 227
 Povezava na celotno besedilo |
